Literature DB >> 20616359

The suitability of matrix assisted laser desorption/ionization time of flight mass spectrometry in a laboratory developed test using cystic fibrosis carrier screening as a model.

Daniel H Farkas1, Nicholas E Miltgen, Jay Stoerker, Dirk van den Boom, W Edward Highsmith, Lesley Cagasan, Ron McCullough, Reinhold Mueller, Lin Tang, John Tynan, Courtney Tate, Allan Bombard.   

Abstract

We designed a laboratory developed test (LDT) by using an open platform for mutation/polymorphism detection. Using a 108-member (mutation plus variant) cystic fibrosis carrier screening panel as a model, we completed the last phase of LDT validation by using matrix-assisted laser desorption/ionization time of flight mass spectrometry. Panel customization was accomplished via specific amplification primer and extension probe design. Amplified genomic DNA was subjected to allele specific, single base extension endpoint analysis by mass spectrometry for inspection of the cystic fibrosis transmembrane regulator gene (NM_000492.3). The panel of mutations and variants was tested against 386 blinded samples supplied by "authority" laboratories highly experienced in cystic fibrosis transmembrane regulator genotyping; >98% concordance was observed. All discrepant and discordant results were resolved satisfactorily. Taken together, these results describe the concluding portion of the LDT validation process and the use of mass spectrometry to detect a large number of complex reactions within a single run as well as its suitability as a platform appropriate for interrogation of scores to hundreds of targets.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20616359      PMCID: PMC2928425          DOI: 10.2353/jmoldx.2010.090233

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  18 in total

1.  Ligase chain reaction to detect Chlamydia trachomatis infection of the cervix.

Authors:  J Schachter; W E Stamm; T C Quinn; W W Andrews; J D Burczak; H H Lee
Journal:  J Clin Microbiol       Date:  1994-10       Impact factor: 5.948

2.  Polymorphism of DNA sequence adjacent to human beta-globin structural gene: relationship to sickle mutation.

Authors:  Y W Kan; A M Dozy
Journal:  Proc Natl Acad Sci U S A       Date:  1978-11       Impact factor: 11.205

3.  Characterization of a novel 21-kb deletion, CFTRdele2,3(21 kb), in the CFTR gene: a cystic fibrosis mutation of Slavic origin common in Central and East Europe.

Authors:  T Dörk; M Macek; F Mekus; B Tümmler; J Tzountzouris; T Casals; A Krebsová; M Koudová; I Sakmaryová; M Macek; V Vávrová; D Zemková; E Ginter; N V Petrova; T Ivaschenko; V Baranov; M Witt; A Pogorzelski; J Bal; C Zékanowsky; K Wagner; M Stuhrmann; I Bauer; H H Seydewitz; T Neumann; S Jakubiczka
Journal:  Hum Genet       Date:  2000-03       Impact factor: 4.132

4.  Immunoglobulin-gene rearrangements as unique clonal markers in human lymphoid neoplasms.

Authors:  A Arnold; J Cossman; A Bakhshi; E S Jaffe; T A Waldmann; S J Korsmeyer
Journal:  N Engl J Med       Date:  1983-12-29       Impact factor: 91.245

5.  Genotype prediction in the fragile X syndrome.

Authors:  M C Hirst; Y Nakahori; S J Knight; C Schwartz; S N Thibodeau; A Roche; T J Flint; J M Connor; J P Fryns; K E Davies
Journal:  J Med Genet       Date:  1991-12       Impact factor: 6.318

6.  Correlation between CTG trinucleotide repeat length and frequency of severe congenital myotonic dystrophy.

Authors:  C Tsilfidis; A E MacKenzie; G Mettler; J Barceló; R G Korneluk
Journal:  Nat Genet       Date:  1992-06       Impact factor: 38.330

7.  Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma.

Authors:  Jennifer Dunlap; Claudia Le; Arielle Shukla; Janice Patterson; Ajia Presnell; Michael C Heinrich; Christopher L Corless; Megan L Troxell
Journal:  Breast Cancer Res Treat       Date:  2009-05-06       Impact factor: 4.872

8.  Simple, efficient, and cost-effective multiplex genotyping with matrix assisted laser desorption/ionization time-of-flight mass spectrometry of hemoglobin beta gene mutations.

Authors:  Wanna Thongnoppakhun; Surasak Jiemsup; Suganya Yongkiettrakul; Chompunut Kanjanakorn; Chanin Limwongse; Prapon Wilairat; Anusorn Vanasant; Nanyawan Rungroj; Pa-Thai Yenchitsomanus
Journal:  J Mol Diagn       Date:  2009-05-21       Impact factor: 5.568

9.  Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded, pan-ethnic mutation panel.

Authors:  R A Heim; E A Sugarman; B A Allitto
Journal:  Genet Med       Date:  2001 May-Jun       Impact factor: 8.822

10.  Profiling critical cancer gene mutations in clinical tumor samples.

Authors:  Laura E MacConaill; Catarina D Campbell; Sarah M Kehoe; Adam J Bass; Charles Hatton; Lili Niu; Matt Davis; Keluo Yao; Megan Hanna; Chandrani Mondal; Lauren Luongo; Caroline M Emery; Alissa C Baker; Juliet Philips; Deborah J Goff; Michelangelo Fiorentino; Mark A Rubin; Kornelia Polyak; Jennifer Chan; Yuexiang Wang; Jonathan A Fletcher; Sandro Santagata; Gianni Corso; Franco Roviello; Ramesh Shivdasani; Mark W Kieran; Keith L Ligon; Charles D Stiles; William C Hahn; Matthew L Meyerson; Levi A Garraway
Journal:  PLoS One       Date:  2009-11-18       Impact factor: 3.240

View more
  2 in total

1.  High-throughput carrier screening using TaqMan allelic discrimination.

Authors:  Anastasia Fedick; Jing Su; Chaim Jalas; Lesley Northrop; Batsal Devkota; Josef Ekstein; Nathan R Treff
Journal:  PLoS One       Date:  2013-03-26       Impact factor: 3.240

Review 2.  Advances in MALDI mass spectrometry in clinical diagnostic applications.

Authors:  Eddy W Y Ng; Melody Y M Wong; Terence C W Poon
Journal:  Top Curr Chem       Date:  2014
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.